GlassScriptPhysician profile
Mazen Khattab
NPI 1205804283
$185,601.15
in general payments reported to CMS, 2019-2025
88 companies · $7,262 in 2025
The $7,262 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $34K · 2021: $18K · 2022: $17K · 2023: $40K · 2024: $8,914 · 2025: $7,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Food and Beverage: $14K · Travel and Lodging: $4,565 · Education: $31.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,820.00 |
| Food and Beverage | $13,789.51 |
| Travel and Lodging | $4,564.61 |
| Education | $31.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $37,377.16 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals LP | $22,572.95 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Seagen INC. | $19,376.47 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Adc Therapeutics America, INC. | $17,209.36 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $11,622.80 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $10,103.30 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $7,354.13 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Pfizer INC. | $7,301.57 | 2019-2025 | |
| Exelixis INC. | $6,915.89 | 2019-2025 | Cabometyx |
| Celgene Corporation | $5,233.78 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Daiichi Sankyo INC. | $4,701.22 | 2022-2025 | Enhertu, Injectafer |
| Stemline Therapeutics INC. | $2,913.47 | 2023-2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $2,780.34 | 2019-2025 | Iclusig, Alunbrig, Fruzaqla |
| Karyopharm Therapeutics INC. | $2,762.69 | 2020-2025 | Xpovio |
| Gilead Sciences, INC. | $2,514.09 | 2019-2025 | Trodelvy |
Show all 88 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,509.55 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Genzyme Corporation | $2,425.97 | 2019-2024 | |
| G1 Therapeutics, INC. | $2,020.04 | 2021-2022 | |
| Taiho Oncology, INC. | $1,863.24 | 2023-2025 | |
| Genmab U.S., INC. | $1,850.10 | 2022-2025 | Epkinly, Tivdak |
| Janssen Global Services, LLC | $1,560.00 | 2021 | |
| Puma Biotechnology, INC. | $1,273.89 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,143.99 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $849.35 | 2019-2025 | Imbruvica, Darzalex, Tecvayli |
| Genentech USA, INC. | $839.27 | 2019-2025 | Alecensa, Polivy, Tecentriq |
| Amgen INC. | $674.99 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Adaptive Biotechnologies Corporation | $673.31 | 2020-2025 | Clonoseq |
| Incyte Corporation | $542.03 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $509.22 | 2020-2024 | Gilotrif |
| Abbvie INC. | $500.41 | 2021-2025 | |
| Secura Bio, INC. | $448.85 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $366.91 | 2019-2023 | Imbruvica, Epkinly |
| Astellas Pharma US INC | $305.81 | 2019-2024 | Padcev, Xospata, Vyloy |
| Tersera Therapeutics LLC | $282.98 | 2021-2025 | Zoladex, Quzyttir, Xermelo |
| Dova Pharmaceuticals | $254.44 | 2020 | |
| Eisai INC. | $235.54 | 2019-2024 | |
| Blueprint Medicines Corporation | $233.34 | 2021-2022 | |
| Array Biopharma INC | $219.69 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Sobi, INC | $202.89 | 2023-2024 | |
| Emd Serono, INC. | $171.73 | 2019-2025 | Tepmetko, Bavencio |
| Jazz Pharmaceuticals INC. | $169.18 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $163.01 | 2021-2025 | Onivyde, Tazverik |
| Servier Pharmaceuticals LLC | $139.46 | 2021-2025 | |
| Kite Pharma, INC. | $135.08 | 2022-2025 | Yescarta |
| Springworks Therapeutics, INC. | $124.65 | 2024-2025 | Ogsiveo |
| Regeneron Healthcare Solutions, INC. | $123.94 | 2021-2025 | Libtayo |
| Galvanize Therapeutics, INC | $119.93 | 2024 | Aliya System |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Sun Pharmaceutical Industries INC. | $99.64 | 2019-2024 | |
| Rigel Pharmaceuticals, INC. | $96.74 | 2022-2024 | Rezlidhia, Tavalisse |
| Beigene USA, INC. | $90.88 | 2023-2024 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $90.35 | 2022-2025 | Monoferric |
| Aveo Pharmaceuticals, INC. | $89.88 | 2021-2024 | Fotivda |
| Sumitomo Pharma America, INC. | $80.08 | 2023-2024 | Orgovyx |
| Janssen Pharmaceuticals, INC | $78.03 | 2019 | |
| Clovis Oncology, INC. | $76.67 | 2019-2022 | |
| Deciphera Pharmaceuticals INC. | $76.20 | 2021-2024 | Qinlock |
| Alexion Pharmaceuticals, INC. | $71.95 | 2019-2025 | Ultomiris |
| Menarini Silicon Biosystems, INC. | $69.21 | 2024 | |
| Kyowa Kirin, INC. | $62.92 | 2022-2024 | Poteligeo |
| Amag Pharmaceuticals, INC. | $60.59 | 2021 | |
| Mirati Therapeutics, INC. | $57.48 | 2023-2024 | Krazati |
| Morphosys, US INC. | $56.56 | 2021-2024 | Monjuvi |
| Teva Pharmaceuticals USA, INC. | $48.82 | 2019-2024 | Truxima |
| Cti Biopharma Corp. | $47.29 | 2022-2023 | Vonjo |
| Agios Pharmaceuticals, INC. | $43.53 | 2019 | |
| Abbott Laboratories | $38.90 | 2022-2023 | Proclaim |
| Global Blood Therapeutics, INC. | $37.85 | 2022 | |
| Spectrum Pharmaceuticals INC. | $36.56 | 2023 | Rolvedon |
| Myriad Genetic Laboratories, INC. | $35.16 | 2021 | |
| Eusa Pharma (US) LLC | $35.11 | 2021-2022 | |
| Beone Medicines USA, INC. | $32.62 | 2025 | Tevimbra |
| Tesaro, INC. | $32.58 | 2019 | |
| Myovant Sciences INC. | $31.95 | 2021-2022 | |
| Pharmaessentia USA Corporation | $24.34 | 2023 | Besremi |
| Recordati_rare_diseases_inc. | $24.12 | 2025 | Enjaymo |
| Acrotech Biopharma INC. | $22.87 | 2025 | Beleodaq |
| Progenics Pharmaceuticals, INC. | $22.75 | 2024 | |
| Coherus Oncology, INC. | $21.39 | 2021 | |
| Immunocore Limited | $18.98 | 2024 | Kimmtrak |
| Chiesi USA, INC. | $17.86 | 2023 | Ferriprox |
| Lexicon Pharmaceuticals, INC. | $17.50 | 2019 | |
| Tempus Ai, INC | $16.20 | 2024 | |
| Apellis Pharmaceuticals, INC. | $14.81 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.54 | 2024 | Neupogen, Neulasta, Avastin |
| Digestive Care, INC. | $13.11 | 2024 | Pertzye |
| Foundation Medicine, INC. | $12.82 | 2019 | |
| Verastem, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
Tukysa $19KEnhertu $4,074Orserdu $2,913Epkinly $1,906Lonsurf $1,863Cabometyx $681Keytruda $620Imbruvica $576Calquence $525Verzenio $407Opdivo $400Trodelvy $385Reblozyl $381Jaypirca $303Xtandi $261Orgovyx $261Retevmo $220Jakafi $214Talzenna $208Kisqali $203Lynparza $199Monjuvi $196Zejula $196Injectafer $181Comirnaty $172Alecensa $171Adcetris $171Tivdak $171Imfinzi $168Lenvima $166Ibrance $165Padcev $160Doptelet $155Pomalyst $153Polivy $151Elrexfio $150Jemperli $143Tecentriq $142Pemazyre $136Welireg $132Sarclisa $124Lunsumio $124Aliya System $120Piqray $118Zoladex $118Mektovi $118Braftovi $118Lorbrena $117Paxlovid $114Pluvicto $111Venclexta $108Yescarta $106Nubeqa $105Tibsovo $105Inlyta $102Darzalex $102Enjaymo $100Scemblix $99.39Perjeta $96.64Ogsiveo $95.94Rozlytrek $95.94Lupron Depot $95.47Gavreto $93.46Vitrakvi $88.93Phesgo $86.02Quzyttir $82.29Xalkori $80.14Cablivi $76.15Tavalisse $75.46Rezlidhia $75.46Stivarga $74.31Columvi $74.00Libtayo $73.34Iclusig $71.90Monoferric $70.44Brukinsa $69.55Cellsearch $69.21Jevtana $67.87Tecvayli $67.41Inqovi $63.24Qinlock $61.00Xofigo $60.89Bosulif $60.55Ojjaara $58.92Fabhalta $57.81Krazati $57.48Carvykti $57.33Bavencio $55.40Fotivda $54.30Pertzye $52.44Opdualag $51.96Oxbryta $49.98Zepzelca $49.58Clonoseq $49.32Onivyde $49.23Ultomiris $48.31Tasigna $48.14Lutathera $45.93Rybrevant $42.86Talvey $42.17
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Khattab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.